ÔçÒÒŮѸÀ×

    1. <form id=SSjMaZxIp><nobr id=SSjMaZxIp></nobr></form>
      <address id=SSjMaZxIp><nobr id=SSjMaZxIp><nobr id=SSjMaZxIp></nobr></nobr></address>

      Current Value of Holding

      $895M

      Shares

      15.8M

      % of Portfolio

      0.65%

      Average Buy Price

      $75

      Avg closing price
      Price range

      50 PRIMECAP Management Biomarin Pharmaceutical - Registered Shares Trades

      PRIMECAP Management's position in Biomarin Pharmaceutical - Registered Shares is currently worth $895M. That's 0.65% of their equity portfolio (44th largest holding). The investor owns 8.00% of the outstanding Biomarin Pharmaceutical - Registered Shares stock. The first Biomarin Pharmaceutical - Registered Shares trade was made in Q1 2013. Since then PRIMECAP Management bought shares 25 more times and sold shares on 24 occasions. The investor's estimated purchase price is $1.18B, resulting in a loss of 24%.

      Avg closing price
      Price range
      Sold 11.3% shares (-2M shares) Q2 2025
      Avg closing price $58.82
      Price range $54.08 - $68.32
      Sold 2.3% shares (-416k shares) Q1 2025
      Avg closing price $67.16
      Price range $61.27 - $72.83
      Sold 3.6% shares (-678k shares) Q4 2024
      Avg closing price $66.95
      Price range $61.93 - $70.53
      Increased shares by 0.4% (+77.4k shares) Q3 2024
      Avg closing price $83.67
      Price range $69.02 - $93.84
      Increased shares by 0.4% (+76.2k shares) Q2 2024
      Avg closing price $83.25
      Price range $74.43 - $92.22
      Increased shares by 1.6% (+300k shares) Q1 2024
      Avg closing price $89.52
      Price range $83.81 - $99.00
      Increased shares by 0.0% (+7.84k shares) Q4 2023
      Avg closing price $88.47
      Price range $76.22 - $98.51
      Increased shares by 0.1% (+22.9k shares) Q3 2023
      Avg closing price $88.98
      Price range $85.07 - $94.48
      Increased shares by 0.8% (+140k shares) Q2 2023
      Avg closing price $94.11
      Price range $86.68 - $100.30
      Increased shares by 3.8% (+663k shares) Q1 2023
      Avg closing price $103.67
      Price range $87.74 - $117.27
      Sold 0.3% shares (-44.6k shares) Q4 2022
      Avg closing price $93.88
      Price range $80.93 - $108.63
      Sold 0.3% shares (-53k shares) Q3 2022
      Avg closing price $89.04
      Price range $82.16 - $96.94
      Sold 0.6% shares (-101k shares) Q2 2022
      Avg closing price $79.62
      Price range $71.48 - $86.85
      Sold 0.1% shares (-25.3k shares) Q1 2022
      Avg closing price $83.67
      Price range $74.28 - $92.69
      Sold 0.7% shares (-133k shares) Q4 2021
      Avg closing price $82.51
      Price range $71.72 - $91.47
      Sold 0.1% shares (-15.7k shares) Q3 2021
      Avg closing price $78.90
      Price range $74.77 - $85.47
      Sold 1.1% shares (-205k shares) Q2 2021
      Avg closing price $79.27
      Price range $75.51 - $84.79
      Increased shares by 0.1% (+9.83k shares) Q1 2021
      Avg closing price $81.69
      Price range $74.73 - $90.69
      Sold 0.2% shares (-43.6k shares) Q4 2020
      Avg closing price $79.28
      Price range $72.61 - $90.20
      Increased shares by 1.7% (+308k shares) Q3 2020
      Avg closing price $101.18
      Price range $71.87 - $131.03

      News about Biomarin Pharmaceutical Inc. - Registered Shares and PRIMECAP Management

      PRIMECAP Management Bolsters Stake in Biomarin Pharmaceutical Inc

      PRIMECAP Management Bolsters Stake in Biomarin Pharmaceutical Inc

      PRIMECAP Management Bolsters Stake in Biomarin Pharmaceutical Inc

      GuruFocus GuruFocus, over 1 year ago
      BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Position Boosted by Panagora Asset Management Inc.

      BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Position Boosted by Panagora Asset Management Inc.

      ¡­ by institutional investors. BioMarin Pharmaceutical Price Performance BMRN opened at ¡­ Sanford C. Bernstein upgraded BioMarin Pharmaceutical from an ¡°under...

      EIN News Pharmaceuticals EIN News Pharmaceuticals, over 1 year ago
      BioMarin may be more of an M&A target with activist Elliott pact - analysts

      BioMarin may be more of an M&A target with activist Elliott pact - analysts

      Biomarin (BMRN) stock rose after activist Elliott Management enteraed a cooepratoon pact and a strategic review committee was established

      Seeking Alpha Seeking Alpha, over 1 year ago
      BioMarin establishes strategic review committee, expands board

      BioMarin establishes strategic review committee, expands board

      BioMarin (BMRN) said it has established a strategic review committee, temporarily expanded its board and entered into a cooperation agreement with Elliott In...

      Seeking Alpha Seeking Alpha, over 1 year ago

      Embed chart

      Easily embed the chart on your blog or website ¨C it will always update automatically!

      HoMEÔçÒÒŮѸÀ×